Blueprint Medicines Co. (NASDAQ: BPMC) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $140.00 price target on the stock.
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.